[{"id":"5037edde-68fc-4ba2-be19-0dd9cdd215d1","acronym":"INFINITE","url":"https://clinicaltrials.gov/study/NCT03710876","created_at":"2025-02-26T07:43:54.912Z","updated_at":"2025-02-26T07:43:54.912Z","phase":"Phase 3","brief_title":"Efficacy \u0026 Safety of RAd-IFN Administered with Celecoxib \u0026 Gemcitabine in Patients with Malignant Pleural Mesothelioma","source_id_and_acronym":"NCT03710876 - INFINITE","lead_sponsor":"Ferring Ventures Limited","biomarkers":" MSLN • EFEMP1","pipe":"","alterations":" ","tags":["MSLN • EFEMP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Adstiladrin (nadofaragene firadenovec-vncg) • celecoxib oral"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 01/21/2019","start_date":" 01/21/2019","primary_txt":" Primary completion: 03/29/2024","primary_completion_date":" 03/29/2024","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-11-08"},{"id":"8b8fa052-0810-47f2-9451-706b3f201858","acronym":"","url":"https://clinicaltrials.gov/study/NCT01687244","created_at":"2021-01-18T07:19:07.786Z","updated_at":"2024-07-02T16:37:19.647Z","phase":"Phase 2","brief_title":"Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer","source_id_and_acronym":"NCT01687244","lead_sponsor":"FKD Therapies Oy","biomarkers":" IFNA1","pipe":" | ","alterations":" IFNA2 elevation","tags":["IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IFNA2 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Adstiladrin (nadofaragene firadenovec-vncg)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 09/01/2012","start_date":" 09/01/2012","primary_txt":" Primary completion: 10/01/2015","primary_completion_date":" 10/01/2015","study_txt":" Completion: 01/01/2016","study_completion_date":" 01/01/2016","last_update_posted":"2017-07-24"}]